Patents by Inventor Robert Schlegl

Robert Schlegl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240026412
    Abstract: The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).
    Type: Application
    Filed: April 9, 2021
    Publication date: January 25, 2024
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Franz Moisi, Markus Hanner, Urban Lundberg
  • Publication number: 20230398210
    Abstract: The present invention relates to an aluminum composition for use as an adjuvant or for use in a method of vaccination, the use of an alum-adjuvanted vaccine composition comprising less than 1.25 ppb copper for increasing bioavailability of an antigen in the vaccine, wherein the antigen is a protein, particularly an OspA protein or a Clostridium difficile toxin A and toxin B fusion protein or a SARS-CoV-2 protein or an hMPV protein, in an aluminum-containing vaccine composition and the use of a radical quenching compound such as L-methionine for increasing bioavailability of a protein antigen in a copper- and aluminum-containing vaccine composition.
    Type: Application
    Filed: April 9, 2021
    Publication date: December 14, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Jürgen Heindl-Wruss
  • Publication number: 20230295245
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: September 14, 2022
    Publication date: September 21, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Publication number: 20230293661
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2022
    Publication date: September 21, 2023
    Applicant: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Publication number: 20230226165
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: March 6, 2023
    Publication date: July 20, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 11684669
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 27, 2023
    Assignees: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
  • Patent number: 11629339
    Abstract: Described herein are processes for the purification of viruses and compositions thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: April 18, 2023
    Assignee: Valneva SE
    Inventors: Robert Schlegl, Michael Weber
  • Publication number: 20230092650
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: March 23, 2023
    Applicants: Dynavax Technologies Corporation, Valneva Austria GmbH
    Inventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
  • Publication number: 20230056142
    Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
    Type: Application
    Filed: July 6, 2022
    Publication date: February 23, 2023
    Applicant: VALNEVA SE
    Inventors: Jana BARBERO CALZADO, Mario NEBENFÜHR, Robert SCHLEGL, Michael WEBER, Jürgen HEINDL-WRUSS
  • Publication number: 20230038284
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 9, 2023
    Applicants: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
  • Patent number: 11484587
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 1, 2022
    Assignee: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lunberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Patent number: 11466058
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: October 11, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Publication number: 20220298493
    Abstract: Described herein are methods for inactivation of viruses with high yield and recovery, and compositions produced by such methods.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 22, 2022
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Jürgen Heindl-Wruss
  • Publication number: 20220288185
    Abstract: The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 15, 2022
    Applicant: Valneva SE
    Inventors: Christoph Reinisch, Robert Schlegl, Jürgen Heindl-Wruss
  • Publication number: 20220273786
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: December 13, 2021
    Publication date: September 1, 2022
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 11331382
    Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: May 17, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Publication number: 20220125917
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Application
    Filed: August 4, 2021
    Publication date: April 28, 2022
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber
  • Publication number: 20220016230
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: August 20, 2021
    Publication date: January 20, 2022
    Applicant: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Patent number: 11219681
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: January 11, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Publication number: 20210322534
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 19, 2018
    Publication date: October 21, 2021
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lunberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon